We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Millennium Pharmaceuticals has initiated a Phase I study of MLN0415, an oral, highly selective, small-molecule inhibitor of IKK2, which targets a major inflammatory pathway.
Targeted Genetics has presented interim results from a Phase I trial of tgAAC09, an investigational HIV/AIDS vaccine candidate based on recombinant adeno-associated virus vector serotype 2 (AAV2).
OrthoLogic announced results of an interim analysis of data from its Phase IIb dose-ranging clinical trial of the synthetic peptide Chrysalin (TP508) in unstable, displaced wrist fractures.
Vanda Pharmaceuticals has completed enrollment in its iloperidone Phase III trial for the treatment of schizophrenia and its VEC-162 Phase III trial for the treatment of transient insomnia.
The FDA has approved several abbreviated new drug applications (ANDAs) for generic versions of Bayer's CIPRO I.V., a drug to treat certain bacterial infections.
InSite Vision announced the FDA has accepted for review the company's new drug application for AzaSite (azithromycin 1 percent ophthalmic solution), indicated for the treatment of bacterial conjunctivitis.
According to a study published in the journal Neurology, Boehringer Ingelheim's Mirapex (pramipexole dihydrochloride) significantly improved symptoms in patients with moderate to severe restless legs syndrome (RLS) versus placebo, as measured by the study's primary efficacy endpoints.